Light Mode
$1.32 ↓ -0.09 (-6.38%) Trading Down from the previous close of $1.41, $0.13 below the day’s high of $1.45
-0.22 (-13.50%) / 6M
Momentum, market sentiment, and recent alerts
PRQR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -40.8%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.